Published in J Alzheimers Dis on January 01, 2011
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol (2013) 1.75
Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology (2013) 1.63
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology (2014) 1.47
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther (2013) 1.44
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One (2016) 1.38
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging (2011) 1.27
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement (2014) 1.26
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry (2014) 1.25
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol (2015) 1.23
Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology (2013) 1.16
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Tau and neurodegenerative disease: the story so far. Nat Rev Neurol (2015) 1.10
CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol (2015) 1.05
A new roadmap for drug development for Alzheimer's disease. Nat Rev Drug Discov (2013) 1.05
Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol (2013) 1.03
Immunotherapy for Alzheimer's disease: past, present and future. Front Aging Neurosci (2014) 0.99
Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol (2013) 0.98
Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One (2012) 0.98
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology (2013) 0.98
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol (2015) 0.97
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis (2013) 0.95
Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology (2013) 0.95
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Template based rotation: a method for functional connectivity analysis with a priori templates. Neuroimage (2014) 0.94
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One (2013) 0.93
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology (2013) 0.92
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Facilitating Alzheimer disease research recruitment. Alzheimer Dis Assoc Disord (2014) 0.89
APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Mol Psychiatry (2015) 0.88
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol (2015) 0.88
Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav (2014) 0.87
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLoS One (2013) 0.85
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag (2015) 0.84
The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. Contemp Clin Trials (2013) 0.84
Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. J Exp Med (2015) 0.83
Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials. PLoS One (2015) 0.83
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci Rep (2015) 0.83
Imaging the Alzheimer brain. J Alzheimers Dis (2011) 0.83
Early neuropsychological detection of Alzheimer's disease. Eur J Clin Nutr (2014) 0.83
Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. J Alzheimers Dis (2013) 0.83
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst) (2015) 0.83
Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep (2014) 0.82
Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations. Am J Neurodegener Dis (2013) 0.81
Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology (2016) 0.81
Progress update: fluid and imaging biomarkers in Alzheimer's disease. Biol Psychiatry (2013) 0.81
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. J Alzheimers Dis (2016) 0.81
Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis (2015) 0.81
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology (2015) 0.80
The need for better AD animal models. Front Pharmacol (2014) 0.80
Genetic variants in Alzheimer disease - molecular and brain network approaches. Nat Rev Neurol (2016) 0.80
Community engagement in diverse populations for Alzheimer disease prevention trials. Alzheimer Dis Assoc Disord (2014) 0.79
Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation. Neurology (2014) 0.79
Social Markers of Mild Cognitive Impairment: Proportion of Word Counts in Free Conversational Speech. Curr Alzheimer Res (2015) 0.79
Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn (2015) 0.79
Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β. Brain (2015) 0.78
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease. Immunotargets Ther (2013) 0.78
An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome. JAMA Neurol (2013) 0.78
Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci (2015) 0.78
Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome. J Alzheimers Dis Parkinsonism (2013) 0.77
Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. Indian J Med Res (2015) 0.77
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition. J Alzheimers Dis (2016) 0.77
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Front Neurol (2015) 0.77
Identification and modification of amyloid-independent phenotypes of APOE4 mice. Exp Neurol (2016) 0.77
Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiol Aging (2015) 0.77
A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure. Alzheimers Dement (N Y) (2016) 0.76
Let Food Be Thy Medicine: Diet, Nutrition, and Biomarkers' Risk of Alzheimer's Disease. Curr Nutr Rep (2015) 0.76
Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease. Curr Geriatr Rep (2015) 0.76
Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges. J Clin Neurol (2016) 0.76
Endpoints in preclinical Alzheimer's disease trials. J Clin Psychiatry (2014) 0.76
Toward precision medicine in Alzheimer's disease. Ann Transl Med (2016) 0.75
Recent Alzheimer's disease research highlights. Alzheimers Res Ther (2012) 0.75
Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials. J Prev Alzheimers Dis (2015) 0.75
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement (2016) 0.75
Evidence for age-associated cognitive decline from Internet game scores. Alzheimers Dement (Amst) (2015) 0.75
Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. Neurology (2016) 0.75
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies. Biomolecules (2015) 0.75
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? Immunotargets Ther (2013) 0.75
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Curr Alzheimer Res (2016) 0.75
Dementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South America. Front Aging Neurosci (2016) 0.75
Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimers Dement (2016) 0.75
Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers? Brain (2015) 0.75
I'd Do Anything for Research, But I Won't Do That: Interest in Pharmacological Interventions in Older Adults Enrolled in a Longitudinal Aging Study. PLoS One (2016) 0.75
Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. Nat Commun (2016) 0.75
Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol (2017) 0.75
Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. Mo Med (2016) 0.75
Recognizing Degenerative Aging as a Treatable Medical Condition: Methodology and Policy. Aging Dis (2017) 0.75
A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley? Neurol Ther (2017) 0.75
Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease. Neurol Ther (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med (1989) 11.07
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA (2002) 9.87
Surrogate end points in clinical trials: are we being misled? Ann Intern Med (1996) 9.81
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA (2008) 8.84
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain (1996) 4.61
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
Physical activity, diet, and risk of Alzheimer disease. JAMA (2009) 4.11
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
2011 Alzheimer's disease facts and figures. Alzheimers Dement (2011) 3.91
Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol (2002) 3.70
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA (1997) 2.81
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry (2008) 2.72
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol (2011) 2.65
Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol (2004) 2.62
Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke (2006) 2.53
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Biomarkers and surrogate markers: an FDA perspective. NeuroRx (2004) 2.20
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology (2004) 1.96
The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med (1996) 1.86
Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage (2008) 1.83
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry (2007) 1.68
Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol (2007) 1.61
Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage (2011) 1.54
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis (2010) 1.54
Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol (2010) 1.45
No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology (2008) 1.45
Visual short-term memory binding deficits in familial Alzheimer's disease. Brain (2010) 1.32
Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging (2008) 1.24
Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol (2008) 1.21
Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology (1999) 1.20
Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology (2001) 1.17
Linking functional and structural brain images with multivariate network analyses: a novel application of the partial least square method. Neuroimage (2009) 1.17
Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage (2009) 1.17
Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes. Neurology (2011) 1.13
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mutat (1997) 1.12
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 1.07
Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. J Neurol Sci (2001) 1.06
Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol (2010) 1.02
Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage (2008) 0.96
Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiol Aging (2008) 0.95
Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene. Am J Alzheimers Dis Other Demen (2003) 0.94
Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int Psychogeriatr (2003) 0.90
Specific deficit of colour-colour short-term memory binding in sporadic and familial Alzheimer's disease. Neuropsychologia (2011) 0.89
Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study. J Clin Exp Neuropsychol (2000) 0.89
Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. Int Psychogeriatr (2007) 0.89
ERP generator anomalies in presymptomatic carriers of the Alzheimer's disease E280A PS-1 mutation. Hum Brain Mapp (2010) 0.87
Linguistic changes in verbal expression: a preclinical marker of Alzheimer's disease. J Int Neuropsychol Soc (2007) 0.87
Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers. Neuroimage (2010) 0.86
Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280A single presenilin-1 mutation. Arch Clin Neuropsychol (2000) 0.83
Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci (1996) 0.82
Cognitive changes in the preclinical phase of familial Alzheimer's disease. J Clin Exp Neuropsychol (2007) 0.81
List of drugs in development for neurodegenerative diseases: update June 2010. Neurodegener Dis (2010) 0.78
Genetic testing must recognize impact of bad news on recipient. Nature (2008) 0.78
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
A microRNA array reveals extensive regulation of microRNAs during brain development. RNA (2003) 9.76
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell (2009) 8.14
Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U S A (2003) 7.95
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells (2005) 6.72
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
The Amphimedon queenslandica genome and the evolution of animal complexity. Nature (2010) 5.11
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res (2008) 3.70
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron (2010) 3.31
Common Kibra alleles are associated with human memory performance. Science (2006) 3.30
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage (2006) 2.94
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol (2003) 2.72
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol (2011) 2.65
What do people at risk for Alzheimer disease think about surrogate consent for research? Neurology (2005) 2.58
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics (2008) 2.50
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem (2003) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
MicroRNAs potentiate neural development. Neuron (2009) 2.25
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther (2010) 2.19
Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement (2007) 2.18
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry (2011) 2.15
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. Neuroimage (2010) 2.04
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. RNA (2007) 2.01
Neural correlates of heart rate variability during emotion. Neuroimage (2008) 1.99
A post-synaptic scaffold at the origin of the animal kingdom. PLoS One (2007) 1.96
A coordinated local translational control point at the synapse involving relief from silencing and MOV10 degradation. Neuron (2009) 1.96
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement (2008) 1.90
Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage (2009) 1.89
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
Age-related regional network of magnetic resonance imaging gray matter in the rhesus macaque. J Neurosci (2008) 1.84
Interpreting scan data acquired from multiple scanners: a study with Alzheimer's disease. Neuroimage (2007) 1.83
Effects of aging on cerebral blood flow, oxygen metabolism, and blood oxygenation level dependent responses to visual stimulation. Hum Brain Mapp (2009) 1.82
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain (2008) 1.82
Training and maintaining memory abilities in healthy older adults: traditional and novel approaches. J Gerontol B Psychol Sci Soc Sci (2007) 1.81
Deletion of the neuron-specific protein delta-catenin leads to severe cognitive and synaptic dysfunction. Curr Biol (2004) 1.80
American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry (2007) 1.79
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol (2013) 1.75
Synaptic tagging -- who's it? Nat Rev Neurosci (2002) 1.75
Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry (2002) 1.75
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry (2009) 1.70
Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry (2007) 1.68
Altered default mode network connectivity in Alzheimer's disease--a resting functional MRI and Bayesian network study. Hum Brain Mapp (2011) 1.67
Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography. Ann N Y Acad Sci (2002) 1.66
MicroRNA regulation of neural stem cells and neurogenesis. J Neurosci (2010) 1.64
Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry (2005) 1.63